



2020 AGIOS PHARMACEUTICALS
**ENVIRONMENTAL, SOCIAL
AND GOVERNANCE REPORT**



AGIOS PHARMACEUTICALS CORPORATE SUSTAINABILITY TEAR SHEET

At Agios, we are committed to building a sustainable business that provides long-term value for all our stakeholders. We support environmental, social and governance (ESG) initiatives that are aligned with our culture and values and that may positively impact the patients we serve, our employees, our communities and our world.

This document contains disclosure of sustainability metrics relevant to Agios' business and strategy. These metrics are aligned with the Sustainability Accounting Standards Board (SASB) standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs). Unless otherwise noted, it covers ESG disclosures for Agios Pharmaceuticals for the period Jan. 1, 2019 through Dec. 31, 2019.



ABOUT US

Agios is a biopharmaceutical company focused on providing important medicines for some of the world's most challenging diseases. Agios is passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients with hematologic malignancies, solid tumors and rare genetic diseases.

Inspired by patients and frustrated by the limitations of conventional approaches to treatment, Agios pioneered a novel path to treating cancer and rare genetic diseases by targeting cellular metabolism. In our first decade, Agios brought two precision oncology medications from our own labs to patients – TIBSOVO® (ivosidenib tablets) for acute myeloid leukemia (AML) patients with an IDH1 mutation and IDHIFA® (enasidenib) for AML patients with an IDH2 mutation. During

that same time period, the Agios team discovered and developed six additional investigational new drug (IND) candidates, including the first pyruvate kinase-R (PKR) activator in development as a potential treatment for a rare hemolytic anemia known as pyruvate kinase deficiency. Agios is leading the way in advancing PKR activation for additional non-malignant hematologic diseases, including thalassemia and sickle cell disease, and the company continues to foster a productive research engine that yields new insights and potential therapeutic approaches. Now entering our next decade, Agios has a differentiated portfolio of preclinical, clinical and commercial programs, unparalleled expertise in cellular metabolism and a committed team that will continue to drive the company's mission to make a difference for patients.

ESG PROGRAM OBJECTIVES

Our vision to make the world a better place is foundational to Agios. We are driven to improve the lives of those fighting life-threatening and life-altering diseases, including genetically defined cancers and rare diseases that have often been overlooked or neglected. We have pioneered two novel therapeutic approaches – IDH inhibition and PKR activation – and continue to focus on creating an environment in which scientific innovation on behalf of patients can thrive. Our ESG program is centered around our commitments to:



PAGE 13
EMPLOYEES



PAGE 23
ETHICS & VALUES

PAGE 07
PATIENTS



PAGE 20
OUR COMMUNITIES & WORLD



Though our commitments are longstanding, we are proud to launch our inaugural ESG report this year. We look forward to continuing to grow our program and build upon these initiatives for years to come.


AGIOS AT A GLANCE

Our people and culture fuel incredible productivity, strategic focus and continuity from early research to market.




FINANCIAL PERFORMANCE

REVENUE



R&D INVESTMENT



OUR COMMITMENT TO PATIENTS

Meet Tamara: A 50-year-old mom, daughter, avid reader and passionate gardener from Minneapolis, Minnesota, living with pyruvate kinase (PK) deficiency – a rare form of hemolytic anemia.

Agios is proud to work toward improving the lives of people like Tamara.



3 GOOD HEALTH
AND WELL-BEING



UN Sustainable Development Goals

CASE STUDY:
PATIENT ACCESS DURING COVID-19 PANDEMIC

In response to the COVID-19 pandemic in early 2020, we quickly created a clinical trial task force to ensure the safety of patients on our clinical studies and to implement plans to enable as many patients to remain in the studies as possible. The task force began meeting daily to address individual situations on a patient-by-patient basis.

In one sample case, we worked to provide TIBSOVO® to a Cairo-based patient enrolled in an ongoing TIBSOVO® clinical trial who has been taking this medicine for four years. The patient typically travels to the U.S. for study visits, but shortly before the Cairo airport was shut down to help contain the COVID-19 outbreak, it became clear the patient would not be able to make it to the study site. We urgently worked with the clinical trial physicians and site and approved a plan within hours to use a concierge-like drug delivery courier to pick up the medicine from the U.S. and fly it to Egypt. As part of our plan, the transportation specialist hand-delivered the study drug to the patient/patient representative and then boarded a return plane the day that the Cairo airport was closed. It is this level of care and urgency on behalf of patients that drives the Agios team every day.



ACCESS TO MEDICINES AND **AFFORDABLE PRICING STRATEGY**

Access to medicines strategy

Agios has a robust patient assistance program, [myAgios](#), that launched in 2018 with the approval of TIBSOVO® (ivosidenib tablets), our first wholly owned product.

Since TIBSOVO® has been on the market, **approximately 40% of patients** have utilized our patient support services programs.

During 2019, the first full year of having a commercially available therapy, about **20% of TIBSOVO® demand was met in the form of free drug provided by Agios** to patients, including those without insurance.

In addition, for 2019, about **75% of TIBSOVO® patients** had an out of pocket expense **under \$25/month**.

Agios also has an Expanded Access Program (EAP) to provide access to our investigational medicines outside the clinical trial process for individuals with serious or life-threatening diseases who have exhausted all treatment options and are not eligible for any appropriate clinical trials. EAPs are available to people in special circumstances whose doctors believe the potential benefit outweighs the risk of receiving an investigational or unapproved medicine, based on the patient's medical history. For more information see [Agios' Expanded Access Programs](#).

Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index

SASB: HC-BP-240A.1

Our goal is to ensure out-of-pocket costs for the individual patient are as reasonable as possible. We price our products based on the clinical benefit they provide. We have a patient assistance program for TIBSOVO® which is detailed [here](#).

List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)

SASB: HC-BP-240A.2

Given the focus on targeted oncology and rare genetic disease medications, Agios' products do not qualify for the WHO List of Prequalified Medicinal Products.

Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period

SASB: HC-BP-240B.1

None.

SAFETY OF CLINICAL TRIAL PARTICIPANTS

Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials

SASB: HC-BP-210A.1

Agios follows all review and approval procedures required by applicable laws and regulations before initiating clinical research. Agios protects patient safety and well-being through appropriate informed consent procedures and Good Clinical Practices. For more information, see [Agios' Code of Business Conduct and Ethics](#).

Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)

SASB: HC-BP-210A.2

1 FDA sponsor inspection and zero findings (VAI or OAI).

Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries

SASB: HC-BP-210A.3

No monetary losses resulting from legal proceedings in 2019. For more information, see Agios' [2020 10-K](#).



DRUG SAFETY AND COUNTERFEIT DRUGS

Total amount of product accepted for take-back, reuse, or disposal

SASB: HC-BP-250A.4

Agios manufactures medicines on a schedule that avoids, to the greatest extent possible, the expiration of product before it is consumed through patient use. In the event that (a) materials do expire before use and are returned or (b) they are found to be unsuitable for release into inventory or (c) they are subject to a recall / withdrawal notice, all materials are destroyed using regulated and monitored incineration processes. As of December 31, 2019, no product returns have been required.

Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting

SASB: HC-BP-260A.1

Agios has successfully implemented serialization practices into its supply chain such that every unit has a unique identifier. As such, the supply chain could be halted the moment any transaction takes place that involved a falsified product.

Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products

SASB: HC-BP-260A.2

Agios has internal processes in place to ensure risks associated with unsafe product are managed. As of December 31, 2019, no alerts have been received.

Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products

SASB: HC-BP-260A.3

None.

List of products listed in the Food and Drug Administration (FDA) MedWatch Safety Alerts for Human Medical Products database

SASB: HC-BP-250A.1

Our wholly owned product TIBSOVO® (ivosidenib tablets) and our partner product IDHIFA® (enasidenib) are included in the FDA MedWatch database.

DRUG SAFETY AND COUNTERFEIT DRUGS

Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System

SASB: HC-BP-250A.2

This information for our products can be found in the FDA's Adverse Event Reporting System [here](#).

Number of recalls issued, total units recalled

SASB: HC-BP-250A.3

Agios has not been subject to any FDA recalls.

Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type

SASB: HC-BP-250A.5

Agios has not had any GMP violations or FDA enforcement actions.



OUR COMMITMENT TO EMPLOYEES

Agios employees at “Development Day,” a series of leadership and growth-oriented workshops run by outside experts and open to all employees.



OUR CULTURE

Our work requires great science. But it also requires an environment where people care – about the work, about each other and about the people who are counting on us the most. At Agios, we believe in our work...and in each other. We approach human resources and people development with this in mind. We are inquisitive, data-driven and purposeful; we listen to feedback, analyze results and use the data to inform program improvements.

All of this has led us to cultivate three guiding pillars:

FLEXIBILITY

Employees with access to flexibility are happier, more engaged and more productive. Flexibility is about individual needs – it's not one size fits all. We encourage a culture that promotes different perspectives, work styles, health & wellness, care of families and productivity.

PSYCHOLOGICAL SAFETY

Based on research initially conducted by Google, we know that high-performing teams exhibit psychological safety – the belief that risk-taking and failure won't be punished, which leads to more creativity and candor and better results.

DELIBERATE DEVELOPMENT

We emphasize providing ongoing opportunities for employees to grow professionally, whether through bringing in external speakers, offering preceptorships in different departments, or providing stretch assignments.

EMPLOYEE RECRUITMENT, ENGAGEMENT AND RETENTION

Discussion of talent recruitment and retention efforts for scientists and research and development personnel

SASB: HC-BP-330A.1

We maintain a focus on the development of all employees, promoting a deliberately developmental culture. For example, our scientists and clinicians are invited to quarterly development sessions to enhance professional skill sets beyond that of their technical/scientific areas. Other talent development and retention programs Agios offers include:

- Tuition reimbursement
- Mentorship, internship and fellowship programs
- Leadership development for managers
- 1-on-1 coaching and presentation skills for employees transitioning from academic, laboratory or physician settings to the corporate environment
- DevelOPPortunities program: Temporary, part-time assignments that provide employees with an opportunity to build new, differentiated skill sets while maintaining current role
- Cross-functional internal moves are encouraged when aligned with employee career interests; in 2019, 10% of open positions at Agios were filled by existing employees
- Equity for employees with flexibility to select the percentage of restricted stock units (RSUs) vs. stock options

Identifying and recruiting top talent is critical to our growing organization. To do so, we leverage internal networks and a variety of external resources such as professional organizations, academic institutions, career sites, job fairs and industry conferences. We take a creative approach to identify and assess a diverse pool of candidates for all our openings including:

- Facilitating interview training for all interviewers
- Providing hiring managers with 360° assessments of candidates using Agios competencies
- Leveraging additional interviewers outside of candidates' functional area to assess value fit and culture add
- Adhering to our equal opportunity employment policy
- Continuously reviewing and improving our interviewing practices

EMPLOYEE RECRUITMENT, ENGAGEMENT AND RETENTION

Employee Engagement

We conduct a full organizational health survey every few years and supplement that with more frequent targeted surveys to measure employee engagement and satisfaction. In Q4 2019, we had a strong participation rate in our organizational health survey with more than 80% of employees indicating:

- They have what they need to perform their jobs successfully and effectively
- They are proud to work at Agios and feel they are part of something meaningful
- They can speak up if they have an idea or if something goes wrong
- Their manager cares about their concerns and that they are supported if they choose to make use of flexible working arrangements.

Agios utilizes these company surveys to form action plans and experiments designed to identify and improve company culture and the employee experience. Progress against action plans is shared with the entire company. For example, in response to employee feedback from the 2018 survey, Agios launched a formal policy on workplace flexibility that we've been operating with for a year. Based on the results from our latest survey, flexibility is now an area of strength for Agios.

Other Agios benefits that have evolved as a result of employee feedback include: discretionary time off policy, formal company shut down during the last week of August and December, expanded parental leave and the introduction of a family leave policy.

Voluntary and Involuntary Turnover Rates

SASB: HC-BP-330A.2

Voluntary and involuntary turnover rates across all levels (executives/senior managers, mid-level managers and professionals) are in alignment with, or lower than, the industry average.




EMPLOYEE RECRUITMENT, ENGAGEMENT AND RETENTION

Diversity Program


Agios is committed to fostering a welcoming and diverse workplace in which individuals from a variety of backgrounds can thrive. Our diversity and inclusion program focuses on valuing three types of differences that shape our team: representative differences (demographic diversity, such as gender, race, ethnicity, sexual orientation), experiential differences (identities based on life experiences that may change over time) and cognitive differences (unique ways of understanding and interpreting the world).

Actions we take to encourage diversity across each of these facets include:



DIVERSITY AND INCLUSION

Snapshot: Gender Diversity



HEALTH AND SAFETY

OSHA Health and Safety Records and Certifications

Agios rates of injuries, illnesses and DART (days away, restricted or transferred) are at or below industry averages.

Health and safety certifications include: CIH (by ABIH), ASP (by BCSP), HAZWOPER (40 hour), RCRA/DOT.

Health and Safety Program

Agios provides regular health and safety training programs for employees. Training for all employees includes: overview during new hire orientation, personal protective equipment (PPE) training, ergonomics, evaluation procedures and first aid training. Lab Training includes: lab safety, chemical safety, bio safety, bloodborne pathogen, respiratory protection, PPE, pathogen-specific training and radiation safety. Other training includes: Lock out tag out, fall protection and ladder safety.

Auditing processes include: external environmental audits conducted every three years, internal audits conducted throughout the year, biosafety audits conducted externally every five years and internally each quarter and chemical hygiene audits conducted internally every year.



OUR COMMITMENT TO OUR COMMUNITIES AND WORLD

At our annual all-company offsite, Agios employees learned about the marine debris problem in Rhode Island, and then put that knowledge into practice by cleaning up 1,415 pounds of trash across multiple stretches of coastline.



12 RESPONSIBLE
CONSUMPTION
AND PRODUCTION



CASE STUDY: **TARGETCANCER FOUNDATION GALA**

As part of our mission to improve the lives of patients with cancer and rare genetic diseases, Agios partners with advocacy groups on important initiatives designed to offer broad and holistic support for these communities. For example, we supported the TargetCancer Foundation (TCF) Gala, the organization's primary annual fundraiser attended by more than 300 supporters, patients, caregivers, doctors, researchers, advocacy partners and industry representatives. The Gala raises critical funds that directly support TCF's rare cancer research and patient support initiatives, as well as initiatives that engage patients in the research process and lower barriers to clinical trial participation.

“Agios’ generous support helped make our 2019 Gala our most successful ever, raising over \$450,000, and the success of that event is helping us keep our programs up and running despite the COVID-19 crisis. We are always thrilled to have Agios representatives attend the event each year as well, as it is extremely meaningful to have such longstanding partners and friends join us for such an important evening.”

Jim Palma, Executive Director, TargetCancer Foundation



COMMUNITY INVOLVEMENT

Charitable Giving

Agios is committed to being a good neighbor in our communities, supporting oncology and rare disease patients and promoting health and science. We have a corporate giving program that identifies important initiatives to support and creates opportunities for employee involvement in these good causes. For more information on Agios' charitable contributions, please see our Commitment to Community page [here](#). Agios employees annually participate in Special Olympics MA's basketball fundraiser [Bioball](#) and in the Leukemia and Lymphoma Society (LLS)'s [Light the Night](#) event for people affected by blood cancers.

ENERGY AND GREENHOUSE GAS EMISSIONS

Energy and Emissions Reduction Efforts

Although Agios leases the majority of our buildings, we have worked with building management to increase the sustainability of our offices through projects such as converting to LED lighting systems, installing energy-efficient appliances and building a 50+ bike storage unit to encourage employees to cycle to work.

ENVIRONMENTAL STEWARDSHIP AND CORPORATE RESPONSIBILITY

Efforts to reduce hazardous waste production

Our hazardous waste program ensures that Agios complies with all relevant local, state and federal regulations for proper signage, storage, weekly inspections, labeling, transporting and disposal of waste. Weekly internal audits are conducted to ensure compliance. In addition, in 2019 a third-party environmental impact audit was conducted, including a review of all relevant documents and a facility inspection. Agios is evaluating additional measures to reduce hazardous waste through improved solvent inventory, purchasing and recycling practices.

Efforts to reduce solid waste production

Agios began our composting program in July 2019, and we have replaced all paper and plastic products in our cafeteria with compostable products. In the first 6 months of the program, Agios composted more than 2 tons of waste. The company currently has single-stream recycling programs and is in the process of exploring additional opportunities to reduce enterprise-wide consumption of single-use plastics.

Efforts to reduce water usage

Agios is currently in the process of evaluating opportunities to reduce our water consumption. We have all new fixtures in our recently renovated facilities that are efficient. We have installed water filling machines to reduce single-use plastic disposable water bottles.

OUR COMMITMENT TO ETHICAL BUSINESS PRACTICES

At Agios, we are committed to conducting business ethically, responsibly and transparently. We hold ourselves to the highest standards and have built strong governance practices to ensure accountability for our actions.



16 PEACE, JUSTICE
AND STRONG
INSTITUTIONS



UN Sustainable Development Goals



“

Because we care about patients in need, about our work and about each other, we also must keep in mind that HOW we accomplish our work is just as important as WHAT we accomplish.

”

Jackie Fouse, CEO, Agios Code of Business Conduct and Ethics

OVERSIGHT OF **SUSTAINABILITY PRACTICES**

ESG Working Group

Our ESG working-group is a cross-functional group of individuals representing the entire organization. This group is overseen by the Vice President of External Communications & Investor Relations who provides updates to the Agios executive leadership team and Board of Directors.

ESG Oversight by the Board of Directors

Our Board receives updates on ESG and sustainability at Agios. Updates come from the CEO, CFO, VP of Facilities and VP of External Communications & IR. In addition, the Board receives regular updates on human capital management from our Chief People Officer.

ETHICAL BUSINESS PRACTICES AND MARKETING

Description of code of ethics governing promotion of off-label use of products

SASB: HC-BP-270A.2

Agios does not promote products for unapproved uses. All promotional communications must meet the requirements of applicable local laws, regulations, industry codes and other applicable guidance documents. Unsolicited requests for information about unapproved uses of Agios products received while conducting promotional communications must be referred to Medical Information or Medical Affairs in accordance with applicable Agios policies and procedures. Additionally, Agios has

clear standards and procedures in place for responding to unsolicited requests for information about unapproved Agios products or unapproved uses of approved Agios products. More information can be found in our Code of Business Conduct and Ethics [here](#).

Description of code of ethics governing interactions with health care professionals

SASB: HC-BP-510A.2

Interactions with healthcare professionals are covered in the Code of Conduct and a number of Compliance policies, including a Policy on Business Courtesies for Healthcare Professionals, Policy on Retaining Healthcare Professionals as Consultants and Speakers and Policy on Promotional, Scientific and Medical Communications. Agios employees engaging with healthcare professionals receive annual training on healthcare professional interactions.

More information can be found in our Code of Business Conduct and Ethics [here](#).

Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

SASB: HC-BP-270A.1

None.

Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery

SASB: HC-BP-510A.1

None.

DATA SECURITY AND PRIVACY

Data security and privacy program

Agios maintains a cybersecurity strategy that is based on four fundamental areas: Policy, Procedure, People and Technology. The Audit Committee of our Board of Directors is briefed on our cybersecurity program periodically throughout the year.

Agios maintains several policies and procedures that describe our employees' responsibilities for accessing computerized systems, handling of data and information and reporting cybersecurity events in a timely manner. Formal training on all policies and procedures relating to acceptable use, reporting lost or stolen equipment, password policy, access to computerized systems and reporting cybersecurity incidents is required by all employees and contractors.

Our Cybersecurity Incident Management Process is used to handle all levels of cybersecurity incidents. Incidents are categorized by severity, impact and risk and tracked for resolution.



POLICY



PROCEDURE



PEOPLE




TECHNOLOGY

CORPORATE GOVERNANCE HIGHLIGHTS

We believe that good corporate governance is important to ensure that Agios is managed for the long-term benefit of our stockholders. We have adopted a [code of business conduct and ethics](#), which applies to all of our officers, directors and employees, corporate governance guidelines and charters for our audit committee, our compensation committee, our nominating and governance committee and our science and technology committee.

Our board of directors has adopted [corporate governance guidelines](#) to assist in the exercise of its duties and responsibilities and to serve the best interests of Agios and our stockholders. These guidelines, which provide a framework for the conduct of our board’s business, provide that:

- our board’s principal responsibility is to oversee the management of Agios;
- a majority of the members of our board shall be independent directors;
- the independent directors meet regularly in executive session;
- directors have full and free access to management and, as necessary and appropriate, independent advisors;
- new directors participate in an orientation program and all directors are expected to participate in continuing director education on an ongoing basis; and
- our board and its committees will conduct a self-evaluation periodically to determine whether they are functioning effectively.



CORPORATE GOVERNANCE HIGHLIGHTS

Best Practices

- Shareholder engagement program
- Diverse board
- Board oversight of ESG
- Board oversight of corporate strategy and risk
- Stock ownership guidelines for executive officers and directors
- Continuing education for directors and orientating for new directors
- Mandatory retirement age of 75

Independence

- Separated CEO and Chair Role
- Independent Lead Director with delineated responsibilities
- 100% independence among standing members of audit, compensation and nominating and corporate governance committees

Accountability

- Regular Board and Committee self-evaluation
- Annual evaluation of CEO by independent directors
- Clawback policy
- Resignation policy

Shareholder Rights

- No poison pill
- One-share, one-vote
- No dual-class common stock

AGIOS AWARDS



FierceBiotech's
2009
Fierce 15



IN VIVO'S
2010
DEAL OF THE YEAR



2020
Women on Boards
“W”
Winning Company



2014
World Economic Forum
Technology
PIONEER



New England Venture
Capital Association's 2018
NEVY Awards
Patient Impact
Award



2018
U.S. Prix Galien Award
BEST PHARMA
PRODUCT NOMINEE
IDHIFA® (enasidenib)

SAFE HARBOR STATEMENT

This communication contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Agios and are subject to significant risks and uncertainties. For example, there can be no guarantee that development of any of Agios' product candidates will successfully commence or continue, and there can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, those related to the impact of the COVID-19 pandemic to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this communication speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.



**CORPORATE
HEADQUARTERS**

AgiOS Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139-4169

www.agios.com

**INTERNATIONAL
HEADQUARTERS**

AgiOS International GmbH
Dammstrasse 19
6300 Zug, Switzerland